CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.

Ulcerative colitis is a gastrointestinal disorder characterized by local inflammation and impaired epithelial barrier. Previous studies demonstrated that CXC chemokine receptor 4 (CXCR4) antagonists could reduce colonic inflammation and mucosal damage in dextran sulfate sodium (DSS)-induced colitis....

Full description

Bibliographic Details
Main Authors: Xian-Ming Xia, Fang-Yu Wang, Ju Zhou, Kai-Feng Hu, Su-Wen Li, Bing-Bing Zou
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3207859?pdf=render
id doaj-450c38207ffc45f8aa07e1423bc33e2b
record_format Article
spelling doaj-450c38207ffc45f8aa07e1423bc33e2b2020-11-25T00:02:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01611e2728210.1371/journal.pone.0027282CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.Xian-Ming XiaFang-Yu WangJu ZhouKai-Feng HuSu-Wen LiBing-Bing ZouUlcerative colitis is a gastrointestinal disorder characterized by local inflammation and impaired epithelial barrier. Previous studies demonstrated that CXC chemokine receptor 4 (CXCR4) antagonists could reduce colonic inflammation and mucosal damage in dextran sulfate sodium (DSS)-induced colitis. Whether CXCR4 antagonist has action on intestinal barrier and the possible mechanism, is largely undefined. In the present study, the experimental colitis was induced by administration of 5% DSS for 7 days, and CXCR4 antagonist AMD3100 was administered intraperitoneally once daily during the study period. For in vitro study, HT-29/B6 colonic cells were treated with cytokines or AMD3100 for 24 h until assay. DSS-induced colitis was characterized by morphologic changes in mice. In AMD3100-treated mice, epithelial destruction, inflammatory infiltration, and submucosal edema were markedly reduced, and the disease activity index was also significantly decreased. Increased intestinal permeability in DSS-induced colitis was also significantly reduced by AMD3100. The expressions of colonic claudin-1, claudin-3, claudin-5, claudin-7 and claudin-8 were markedly decreased after DSS administration, whereas colonic claudin-2 expression was significantly decreased. Treatment with AMD3100 prevented all these changes. However, AMD3100 had no influence on claudin-3, claudin-5, claudin-7 and claudin-8 expression in HT-29/B6 cells. Cytokines as TNF-α, IL-6, and IFN-γ increased apoptosis and monolayer permeability, inhibited the wound-healing and the claudin-3, claudin-7 and claudin-8 expression in HT-29/B6 cells. We suggest that AMD3100 acted on colonic claudin expression and intestinal barrier function, at least partly, in a cytokine-dependent pathway.http://europepmc.org/articles/PMC3207859?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Xian-Ming Xia
Fang-Yu Wang
Ju Zhou
Kai-Feng Hu
Su-Wen Li
Bing-Bing Zou
spellingShingle Xian-Ming Xia
Fang-Yu Wang
Ju Zhou
Kai-Feng Hu
Su-Wen Li
Bing-Bing Zou
CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.
PLoS ONE
author_facet Xian-Ming Xia
Fang-Yu Wang
Ju Zhou
Kai-Feng Hu
Su-Wen Li
Bing-Bing Zou
author_sort Xian-Ming Xia
title CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.
title_short CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.
title_full CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.
title_fullStr CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.
title_full_unstemmed CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.
title_sort cxcr4 antagonist amd3100 modulates claudin expression and intestinal barrier function in experimental colitis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description Ulcerative colitis is a gastrointestinal disorder characterized by local inflammation and impaired epithelial barrier. Previous studies demonstrated that CXC chemokine receptor 4 (CXCR4) antagonists could reduce colonic inflammation and mucosal damage in dextran sulfate sodium (DSS)-induced colitis. Whether CXCR4 antagonist has action on intestinal barrier and the possible mechanism, is largely undefined. In the present study, the experimental colitis was induced by administration of 5% DSS for 7 days, and CXCR4 antagonist AMD3100 was administered intraperitoneally once daily during the study period. For in vitro study, HT-29/B6 colonic cells were treated with cytokines or AMD3100 for 24 h until assay. DSS-induced colitis was characterized by morphologic changes in mice. In AMD3100-treated mice, epithelial destruction, inflammatory infiltration, and submucosal edema were markedly reduced, and the disease activity index was also significantly decreased. Increased intestinal permeability in DSS-induced colitis was also significantly reduced by AMD3100. The expressions of colonic claudin-1, claudin-3, claudin-5, claudin-7 and claudin-8 were markedly decreased after DSS administration, whereas colonic claudin-2 expression was significantly decreased. Treatment with AMD3100 prevented all these changes. However, AMD3100 had no influence on claudin-3, claudin-5, claudin-7 and claudin-8 expression in HT-29/B6 cells. Cytokines as TNF-α, IL-6, and IFN-γ increased apoptosis and monolayer permeability, inhibited the wound-healing and the claudin-3, claudin-7 and claudin-8 expression in HT-29/B6 cells. We suggest that AMD3100 acted on colonic claudin expression and intestinal barrier function, at least partly, in a cytokine-dependent pathway.
url http://europepmc.org/articles/PMC3207859?pdf=render
work_keys_str_mv AT xianmingxia cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis
AT fangyuwang cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis
AT juzhou cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis
AT kaifenghu cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis
AT suwenli cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis
AT bingbingzou cxcr4antagonistamd3100modulatesclaudinexpressionandintestinalbarrierfunctioninexperimentalcolitis
_version_ 1725439097108955136